Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hepatitis C
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hepatitis C
    Low-Dose Pegylated Interferon Regimen Shows Sustained Viral Response in Patients With Hepatitis C Genotype 1: Presented at EASL - (DGDispatch)
    TopAbstracts in Hepatitis C 04/29/2008 - (DGNews)
    Taribavirin Comparable in Efficacy to Ribavirin and Results in Less Anaemia in Patients With Chronic Hepatitis C: Presented at EASL - (DGDispatch)
    Nitazoxanide Demonstrates Activity in Treatment-Naive Patients With Hepatitis C Virus Genotype 4: Presented at EASL - (DGDispatch)
    R7128 is Safe, Effective in Short-Term for Patients With Hepatitis C Virus Genotype 1: Presented at EASL - (DGDispatch)

    News archive

     Recent webcasts/CME - Hepatitis C

    Webcasts/CME archive

     Recent cases - Hepatitis C
      Recurrence of Hepatitis C Virus During Leucocytopenia and Spontaneous Clearance after Recovery from Cytopenia: A Case Report
      Successful Outcome of a Pregnancy in Women with Advanced Cirrhosis Due to Hepatitis B Surface Antigenemia, Delta Super-Infection and Hepatitis C Co-Infection: A Case Report
      Extensive Psoriasis Induced by Pegylated Interferon: A Case Report
      Acquired Apolipoprotein B Deficiency with Chronic Hepatitis C Virus Infection
      Hepatitis C Virus-Related Fibrosing Cholestatic Hepatitis in s Renal Transplant Recipient

      Cases archive
        




      my personal edition > hepatitis c > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Human Immunodeficiency Virus Worsens Hepatitis C Outlook For Drug Injectors

      A DGReview of :"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study (*Human Study*)"
      Hepatology

      12/14/2001
      By Anne MacLennan


      Interferon therapy has a protective effect against cirrhosis related to human immunodeficiency virus no matter what the patient's HIV status is.

      This is one finding of a long-term retrospective cohort study of the influence of human immunodeficiency virus (HIV) co-infection on chronic hepatitis C in injection drug users.

      Human immunodeficiency virus (HIV) coinfection was also found in this study to worsen the outcome of chronic hepatitis C, increasing both serum hepatitis C virus (HCV)-RNA level and liver damage and decreasing sustained response to interferon therapy.

      Age and alcohol were found to be cofactors linked with cirrhosis and mortality.

      Researchers also considered the impact of HIV on HCV-RNA load, histologic activity index, response to interferon therapy and liver-related death. Age, alcohol consumption, immune status and HCV-related virologic factors were included.

      Study participants were 80 HIV-positive and 80 HIV-negative injection drug users enrolled between 1980 and 1995 and matched by age, gender, and duration of HCV infection. Participants were followed up over 52 months, and primary outcome measure was progression to cirrhosis.

      In HIV-positive patients, chronic hepatitis C was characterised by higher serum HCV-RNA levels, higher total Knodell score, and poorer sustained response to interferon therapy. High serum HCV-RNA level was linked with low CD4-lymphocyte count.

      Whereas increased fibrosis was related to decreased CD4-lymphocyte count, necroinflammatory score was higher in HIV-positive patients independently of the CD4-lymphocyte count.

      In HIV-positive patients with low CD4 cell count and in interferon-untreated patients, progression to cirrhosis was accelerated independently of age at HCV infection.

      Cirrhosis caused death in five HIV-positive patients.

      Risk of death related to cirrhosis was increased in heavy drinkers and in HIV-positive patients with CD4 cell count less than 200/mm3.

      Vincent Di Martino and colleagues from the Service d'Hepatologie, INSERM U481 et Centre de Recherche Claude Bernard sur les Hepatites Virales, Hopital Beaujon, Clichy, France did this analysis on the influence of HIV infection on chronic hepatitis C via multivariate analysis.
      HEPATOLOGY 2001;34:1193-1199. "The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study (*Human Study*)"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send